Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

American Heart Journal

Volumn 168, Issue 5, 2014, Pages 682-689.e1

  Schwartz, Gregory G ^a,p   Bessac, Laurence ^b   Berdan, Lisa G ^c   Bhatt, Deepak L ^d   Bittner, Vera ^e   Diaz, Rafael ^f   Goodman, Shaun G ^g   Hanotin, Corinne ^b   Harrington, Robert A ^h   Jukema, J Wouter ⁱ   Mahaffey, Kenneth W ^h   Moryusef, Angèle ^b   Pordy, Robert ^j   Roe, Matthew T ^c   Rorick, Tyrus ^c   Sasiela, William J ^j   Shirodaria, Cheerag ^k   Szarek, Michael ^l   Tamby, Jean François ^b   Tricoci, Pierluigi ^c   White, Harvey ^m   Zeiher, Andreas ⁿ   Steg, Philippe Gabriel ^o   more..

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b SANOFI   (France)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f Etudios Cardiologica Latin America Rosario   (Argentina)

^g UNIVERSITY OF ALBERTA   (Canada)

^h STANFORD UNIVERSITY   (United States)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^j REGENERON PHARMACEUTICALS INC   (United States)

^k Department of Environmental Air Quality   (United Kingdom)

^l SUNY DOWNSTATE MEDICAL CENTER   (United States)

^m AUCKLAND CITY HOSPITAL   (New Zealand)

ⁿ GOETHE UNIVERSITY   (Germany)

^o ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^p VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PCSK9 PROTEIN; PLACEBO; PROTEIN; ROSUVASTATIN; UNCLASSIFIED DRUG; FLUOROBENZENE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SERINE PROTEINASE; SULFONAMIDE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MORBIDITY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEADY STATE; STUDY DESIGN; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; ANGINA, UNSTABLE; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COMPLICATION; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; HYPERCHOLESTEROLEMIA; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PHASE 3 CLINICAL TRIAL; STROKE; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ANGINA, UNSTABLE; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FLUOROBENZENES; HEPTANOIC ACIDS; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MYOCARDIAL INFARCTION; PROPROTEIN CONVERTASES; PYRIMIDINES; PYRROLES; SERINE ENDOPEPTIDASES; STROKE; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84908322310     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.07.028     Document Type: Article

References (27)

1. G.G. Schwartz, A.G. Olsson, and M. Abt Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 22 2012 2089 2099
2. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 11 2009 1045 1057
3. G.G. Schwartz, A.G. Olsson, and M.D. Ezekowitz Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial JAMA 285 13 2001 1711 1718
4. C.P. Cannon, E. Braunwald, and C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 15 2004 1495 1504
5. K.A. Fox, K.F. Carruthers, and D.R. Dunbar Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study) Eur Heart J 31 22 2010 2755 2764
6. J. Stamler, D. Wentworth, and J.D. Neaton Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT) JAMA 256 20 1986 2823 2828
7. C. Baigent, L. Blackwell, and J. Emberson Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 9753 2010 1670 1681
8. S.D. Wiviott, C.P. Cannon, and D.A. Morrow Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy J Am Coll Cardiol 46 8 2005 1411 1416
9. D.G. Karalis, B. Victor, and L. Ahedor Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients Cholesterol 2012 2012 861924
10. K. Kotseva, D. Wood, and B.G. De Backer EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries Eur J Cardiovasc Prev Rehabil 16 2 2009 121 137
11. R.Q. Do, R.A. Vogel, and G.G. Schwartz PCSK9 inhibitors: potential in cardiovascular therapeutics Curr Cardiol Rep 15 3 2013 345
12. J.C. Cohen, E. Boerwinkle, and T.H. Mosley Jr. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 12 2006 1264 1272
13. R.P. Naoumova, I. Tosi, and D. Patel Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response Arterioscler Thromb Vasc Biol 25 12 2005 2654 2660
14. G. Welder, I. Zineh, and M.A. Pacanowski High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol J Lipid Res 51 9 2010 2714 2721
15. E.A. Stein, S. Mellis, and G.D. Yancopoulos Effect of a monoclonal antibody to PCSK9 on LDL cholesterol N Engl J Med 366 12 2012 1108 1118
16. J.M. McKenney, M.J. Koren, and D.J. Kereiakes Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 59 25 2012 2344 2353
17. E.A. Stein, D. Gipe, and J. Bergeron Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Lancet 380 9836 2012 29 36
18. E.M. Roth, J.M. McKenney, and C. Hanotin Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia N Engl J Med 367 20 2012 1891 1900
19. S.S. Martin, M.J. Blaha, and M.B. Elshazly Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications J Am Coll Cardiol 62 8 2013 732 739
20. P. Dolan Modeling valuations for EuroQol health states Med Care 35 11 1997 1095 1108
21. C.P. Cannon, W.S. Weintraub, and L.A. Demopoulos Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban N Engl J Med 344 25 2001 1879 1887
22. W.E. Boden, J.L. Probstfield, and T. Anderson Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 24 2011 2255 2267
23. J.A. Dormandy, B. Charbonnel, and D.J. Eckland Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 9493 2005 1279 1289
24. H.N. Ginsberg, M.B. Elam, and L.C. Lovato Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 17 2010 1563 1574
25. C.P. Cannon, R.P. Giugliano, and M.A. Blazing Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes Am Heart J 156 5 2008 826 832
26. N.J. Stone, J. Robinson, and A.H. Lichtenstein ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 129 25 Suppl 2 2014 S1 S45
27. K. Thygesen, J.S. Alpert, and A.S. Jaffe Third universal definition of myocardial infarction Eur Heart J 33 20 2012 2551 2567